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Background: Tuberculous meningitis (TBM) is the second most 
common cause of meningitis in sub-Saharan Africa and is notoriously 
difficult to diagnose. We describe the impact of improved TBM 
diagnostics over 6.5 years at two Ugandan referral hospitals. 
Methods: Cohort one received cerebrospinal fluid (CSF) smear 
microscopy only (2010-2013). Cohort two received smear microscopy 
and Xpert MTB/Rif (Xpert) on 1ml unprocessed CSF at physician 
discretion (2011-2013). Cohort three received smear 
microscopy, routine liquid-media culture and Xpert on large volume 
centrifuged CSF (2013-2017) for all meningitis suspects with a negative 
CSF cryptococcal antigen. We compared rates of microbiologically 
confirmed TBM and hospital outcomes over time. 
Results: 1672 HIV-infected adults presenting with suspected 
meningitis underwent lumbar puncture, of which 33% (558/1672) had 
negative CSF cryptococcal antigen and 12% (195/1672) were treated 
for TB meningitis. Over the study period, microbiological confirmation 
of TBM increased from 3% to 41% (P<0.01) and there was a decline in 
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in-hospital mortality from 57% to 41% (P=0.27) amongst those with a 
known outcome. Adjusting for definite TBM diagnosis and 
antiretroviral therapy use, and using imputed data, assuming 50% of 
those with an unknown outcome died, the odds of dying were nearly 
twice as high in cohort one (adjusted odds ratio 1.7, 95% CI 0.7 to 4.4) 
compared to cohort three.  Sensitivity of Xpert was 63% (38/60) and 
culture was 65% (39/60) against a composite reference standard. 
Conclusions: As TBM diagnostics have improved, microbiologically-
confirmed TBM diagnoses have increased and in-hospital mortality 
has declined. Yet, mortality due to TB meningitis remains 
unacceptably high and further measures are needed to improve 
outcomes from TBM in Uganda.
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Introduction
Tuberculous meningitis (TBM) is the second most common 
cause of adult meningitis in sub-Saharan Africa1,2, account-
ing for one to five percent of the 10.4 million tuberculosis (TB) 
cases reported worldwide in 20163. Despite treatment, TBM 
outcomes are poor with 19–28% mortality in HIV-uninfected 
persons and 40–67% mortality in HIV-infected patients in 
addition to long-term disability is frequent among survivors4–6.
Insidious symptom onset in persons with TBM leads to delay 
in seeking care and increasing disease severity at presentation 
correlates with higher mortality7. Further, the paucibacillary 
nature of TBM increases the difficulty in confirming diagno-
sis once care is sought, also contributing to high mortality8. 
Cerebrospinal fluid (CSF) smear microscopy for acid-fast bacilli 
(AFB smear) has poor sensitivity (~10–20%) in routine practice7. 
Culture has improved sensitivity (~50–60%) but is not widely 
available in many resource constrained settings and commonly 
takes at least 2–3 weeks for liquid culture growth, which is too 
slow to guide decision-making at the time of presentation8. 
In 2013, the World Health Organization endorsed the Xpert 
MTB/RIF (Xpert) assay (Cepheid, Sunnyvale, California, USA), 
a cartridge-based, polymerase chain reaction assay with a run 
time of 113 minutes, as the preferred initial test to investigate 
TB meningitis on the basis of a meta-analysis of 13 studies9. 
Of the two major studies included in the meta-analysis, Patel 
and colleagues reported 67% sensitivity against microbiologi-
cally proven TBM and 36% against consensus clinical case 
definitions, while Nhu and colleagues showed 59% sensitiv-
ity against the same case definitions10–12. Additionally, use of 
a larger volume of centrifuged CSF improves sensitivity of 
Xpert10,13. Yet, inadequate negative predictive value means that 
Xpert cannot substitute for clinical judgement14.
There is evidence that use of Xpert for diagnosis of pulmonary 
TB reduces diagnostic delay, increases the rate of same day treat-
ment, and decreases usage of empiric treatment15,16. However 
for pulmonary TB, Xpert has not been shown to decrease 
mortality16–18. Yet, lessening diagnostic delay in persons with 
TBM may be more likely to lead to improved outcomes as 
compared to pulmonary TB given the high early mortality 
of TBM19. Whether routine use of Xpert for investigation of 
suspected TBM has made an impact on mortality has not yet 
been investigated.
Herein we describe TBM diagnosis and outcomes over a 




Adults presenting with symptoms of meningitis to Mulago 
National Referral Hospital, Kampala, and Mbarara Regional 
Referral Hospital, Mbarara, Uganda were assessed for eligibil-
ity for enrolment in two consecutive clinical trials investigating 
cryptococcal meningitis (www.clinicaltrials.gov: NCT01075152 – 
Cryptococcal Optimal Antiretroviral Timing, NCT01802385 – 
Adjunctive Sertraline for the Treatment of Cryptococcal 
Meningitis) beginning November 22, 2010. Patient screening 
continued until 28th May 2017. Baseline demographics, clinical 
and outcome data on all screened patients were routinely 
collected as part of the screening process. Any patient who 
received testing for TBM was eligible to be included in this 
study.
Microbiologically proven (definite) TB meningitis was defined 
as any positive AFB smear, culture or Xpert result from CSF 
testing. Consensus uniform case definitions were used to cat-
egorise patients as definite, probable, possible or not TBM11. 
In addition to the consensus case definitions, clinical TBM was 
defined as subjects without a positive microbiologic result, 
but who were treated empirically for TBM treatment due to 
high clinical suspicion. TBM treatment included 12 months 
of antituberculous therapy with 6–8 weeks of adjunctive 
corticosteroids as per Ugandan guidelines20. 
Cohort definitions and diagnostic tests used
Cohort one (16th November 2010 until 28th May 2013) received 
only CSF AFB smear testing (Figure 1). If available, 1mL 
cryopreserved CSF was later tested with Xpert MTB/Rif 
when Xpert became available. Cohort two (1st April 2011 until 
10th November 2013) underwent CSF AFB smear and Xpert 
MTB/Rif on a 1ml sample of uncentrifuged CSF. Testing was 
performed at physician discretion when there was lymphocytic 
pleocytosis and/or high degree of clinical suspicion. In the 
period of overlap of cohort one and two (April 2011–May 2013), 
Xpert testing was not being done on a routine basis; subjects 
were included in cohort two when Xpert was done in real-time 
and in cohort one if Xpert was not done, or only done at a 
later date on cryopreserved specimens.
In cohort three (11th November 2013 until 28th May 2017) all 
cryptococcal antigen negative (IMMY, Norman, Oklahoma, 
USA) patients were systematically investigated for the pres-
ence of TB meningitis, irrespective of physician discretion. 
Subjects had comprehensive testing for TBM with CSF AFB 
smear (Mulago Hospital only), Xpert MTB/Rif on large volume 
centrifuged CSF13 and CSF Mycobacteria Growth Inhibitor Tube 
culture (MGIT, Becton Dickinson, Franklin Lakes, USA). AFB 
smear was discontinued in Mbarara in 2013 as the sensitivity 
was deemed too low to justify further use. In patients with a 
confirmed diagnosis of cryptococcal meningitis (CM), if TBM 
co-infection was suspected, patients would be investigated 
for TBM at the physician’s discretion. 
Assessment of outcome
In-hospital outcome was determined from case report forms, 
hospital medical records or follow-up telephone calls with the 
patient or their surrogate where hospital outcome was unknown. 
The outcome was categorised as discharged alive, deceased prior 
to hospital discharge or unknown (i.e. self-discharged against 
medical advice in an imminently terminal patient, hospital 
outcome undetermined, transferred to another facility).
Statistical methods
Comparisons of categorical and continuous demographic and 
clinical characteristics by cohort were performed using Fisher’s 
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Figure 1. Timeline illustrating evolution of diagnostic testing.
exact tests and Kruskal-Wallis tests, respectively. Sensitivity 
of Xpert MTB/Rif was evaluated against a composite reference 
standard (any positive CSF test - AFB smear, Xpert or culture 
i.e. definite TBM according to the uniform case definition)11. 
A separate analysis was conducted against the uniform case 
definition of probable or definite TBM11. Concordance between 
Xpert MTB/Rif and culture was evaluated with a kappa 
statistic and McNemar’s test. Invalid tests (e.g. culture 
contamination, Xpert error) were counted as negative results. 
Mortality was first compared by cohort for participants with a 
known outcome using Fisher’s exact test. Data for patients with 
unknown outcome was imputed to assume first that 50% within 
each cohort died, or that 75% died (both within the expected 
mortality range for this population). Odds ratios and 95% 
confidence intervals were computed from multivariable logistic 
regression models with these imputed data, adjusted for 1) 
ART status, and 2) ART status and definite TBM diagnosis. 
Imputations were repeated with new random assignments to 
confirm results. Analyses were conducted using SAS version 
9.4 (The SAS Institute, Cary, NC) and p-values <0.05 were 
considered statistically significant.
Ethics
Institutional review board approvals for the studies were obtained 
locally in Uganda [ASTRO: Mulago Hospital Research Ethics 
Committee (approval number, MREC 429); COAT: Makerere 
University School of Medicine Research and Ethics Com-
mittee (approval number, REC Ref No. 2009–022)], from the 
University of Minnesota (USA), and by the Uganda National 
Council of Science and Technology Written informed con-
sent for screening or participation in the studies was obtained 
from all participants or from their surrogates (e.g. family 
member or guardian) where the patient had altered mental 
status and did not have the capacity to provide consent.
Results
Participant characteristics
Over the study period, 1672 patients with meningitis symptoms 
were assessed and underwent lumbar puncture: 1058 (63%) 
had a positive CSF cryptococcal antigen test, 558 (33%) had 
negative CSF cryptococcal antigen test (data missing, n=56). 
A total of 195 subjects were treated for TBM. Overall 61% 
were male, median age was 35 years (IQR 30–42), 96% were 
HIV-positive, median CD4 count was 78 cells/μL (IQR 26–191) 
and the majority (69%) presented with British Medical 
Research Council severity grade II disease, see Table 1. Base-
line characteristics were similar between cohorts with the 
exception of antiretroviral (ART) experience; 0% of participants 
were on ART in cohort one compared to 61% in cohort three 
(P<0.01).
Among the 76 cases of microbiologically proven TBM in this 
population with advanced HIV infection, 33% (25/76) had an 
acellular CSF (white cells <5 cells/μL) at presentation, and 
4% (3/76) had a normal CSF profile (CSF cells <5 cells/μL, 
protein <45 mg/dL, and glucose >2.2mmol/l).
Method of diagnosis
Microbiological confirmation of TBM was made in 38% 
(74/195) of cases. The proportion of cases with microbiologi-
cally confirmed TBM (definite TBM) increased significantly, 
from 3% (1/33) in cohort one to 87% (13/15) in cohort 2 and 
41% (60/147) in cohort 3 (P<0.01). Categorisation by uniform 
case definition is summarised in Table 2.
There was a marked difference in physician threshold for 
empiric TBM therapy between the two clinical sites. In cohort 
three, Mulago Hospital recorded 44 cases of which 77% (34/44) 
were microbiologically confirmed and 23% (10/44) were 
empirically treated, whilst Mbarara Hospital recorded 103 
cases of which 25% (26/103) were microbiologically confirmed 
and 75% (77/103) were empirically treated.
Diagnostic accuracy of Xpert MTB/Rif
Xpert MTB/Rif was positive in 51 of 455 tested (11%), 
MGIT culture positive in 39 of 321 (12%) tested, AFB 
stain positive on 5 of 818 tested (1%), as summarised in 
Table 2.
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Table 1. Demographics, HIV details and outcomes of cohort.
N with 
data
Cohort 1  
Nov 2010 to 
May 2013
Cohort 2  
Apr 2011 to 
Nov 2013
Cohort 3  
Nov 2013 to 
May 2017





N in TBM case cohort 33 15 147 195
Demographics
Sex 195 0.58
      Male 18 (55%) 8 (53%) 92 (63%) 118 (61%)
Age 195 0.33
      Median (IQR) 33 (29, 38) 35 (29, 40) 35 (30, 43) 35 (30, 43)
HIV details
HIV status, n (%) 195 1.00
      HIV-positive 32 (97%) 15 (100%) 141 (96%) 188 (96%)
ART status, n (%) 179 <0.01
      On ART 0 (0%) 4 (27%) 80 (61%) 84 (47%)
      ART naive 32 (100%) 11 (73%) 52 (39%) 95 (53%)
CD4 131 0.30
      Median (IQR) 12 (7, 121) 148 (54, 169) 78 (26, 206) 78 (26, 191)
TBM details
MRC severity grade, 
n (%) 191 0.13
      I 9 (27%) 4 (31%) 20 (14%) 33 (17%)
      II 22 (67%) 7 (54%) 102 (70%) 131 (69%)
      III 2 (6%) 2 (15%) 23 (16%) 27 (14%)
*P-values from Fisher’s exact tests for categorical variables and Kruskal-Wallis tests for continuous variables.
Diagnostic accuracy of Xpert and MGIT were analysed in 
cohort three, when both assays were done routinely, and 60 
participants had a microbiologically confirmed diagnosis (com-
posite reference standard). Sensitivity of Xpert was 63% (38/60) 
against the composite reference standard and 54% (38/71) 
against the uniform case definition (probable or definite TBM). 
Sensitivity of MGIT culture was 65% (39/60) against the 
composite reference standard of definite microbiologic- 
confirmed TBM and 55% (39/71) against uniform case definition 
for probable or definite TBM.
Concordance between Xpert MTB/Rif and MGIT culture was ana-
lysed in the 118 with both Xpert and MGIT culture results avail-
able. Either Xpert or MGIT culture was positive in 56 patients, of 
which only 30% (17/56) were positive by both modalities (kappa 
0.23 95% CI [0.04, 0.41], p=0.01 (Figure 2). Neither method 
diagnosed significantly more cases than the other (p=0.42). 
Outcomes
Hospital outcome was known for 142 participants, 53 had 
unknown outcomes or self-discharged against medical advice. 
Median time to death was 3 days (IQR 1–9 days) among those 
known to have died, and median length of hospitalization was 7 
days (IQR 4–10 days) for participants known to have survived 
to hospital discharge. Among those with known outcomes, there 
was a non-significant decline in mortality from 57% in cohort 
one to 41% in cohort three (p=0.27) (Table 3). Assuming that 
50% of those with unknown outcome died, and adjusting for 
ART status and definite TBM diagnosis at hospitalization, the 
odds of dying were approximately twice as high for cohort 
one (aOR 1.7 95% CI [0.7, 4.4]) and cohort two (1.8 [0.6, 5.6]) 
as compared to cohort three. Assuming that 75% of those with 
unknown outcome died, adjusted odds of death increase fur-
ther, cohort one (4.0 [1.5, 10.9]) and cohort two (2.0 [0.6,6.7]) 
compared to cohort three (Table 3, Figure 3).
Discussion
Rapid molecular diagnostics have been predicted to reduce 
TB-related mortality21 but no prior studies have looked at the 
impact of Xpert on TBM-related mortality. Here we report 
clinical outcomes among hospitalized Ugandans treated for 
TB meningitis over a 6.5-year period. In-hospital mortality 
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Figure 2. Venn diagram Illustrating the overlap of positive MGIT culture and Xpert test results in the n=118 samples tested with both 
assays. A total of 118 adults were tested with both MGIT culture and Xpert, of which 22 were positive by MGIT culture, 17 by Xpert and 17 by 
both tests. Neither test performed better than the other, p=0.423 by McNemar’s. A kappa statistics value of 0.23 95%CI [0.04, 0.41], p=0.01, 
suggests only slight agreement of the two assays.
Table 2. Methods of Diagnosis.
Cohort 1 Cohort 2 Cohort 3






All meningitis patients screened
Total number 471 71 1130 1672
    Cryptococcal Antigen positive 269 31 758 1058
    Cryptococcal Antigen negative 187 38 333 558
TBM diagnostic tests performed
CSF AFB smear microscopy*
    N AFB performed 466 71 281 818
    N AFB positive 1 (0%) 0 (0%) 4 (2%) 5 (1%)
CSF TB culture
    N TB culture performed 0 0 321 321
    N TB culture positive 0 0 39 (12%) 39 (12%)
CSF Xpert MTB/Rif
    N Xpert performed (realtime) 0 71 384 455
    N Xpert positive 0 13 (18%) 38 (10%) 51 (11%)
Uniform case definition
    Definite 1 (3%) 13 (87%) 60 (41%) 74 (38%) <.01
    Probable 5 (15%) 2 (13%) 11 (7%) 18 (9%)
    Possible 22 (67%) 0 (0%) 53 (36%) 75 (38%)
    Not 5 (15%) 0 (0%) 23 (16%) 28 (14%)
Prior to November, 2013 any patient not prospectively tested with Xpert was considered in Cohort 1
*AFB smear was initially performed on all meningitis patients regardless of CSF Cryptococcal antigen result. 
From October 2013, it was only performed on those with a negative Cryptococcal antigen, and was later stopped 
altogether in Mbarara.
$P-value from Fisher’s exact test
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Table 3. Hospital outcomes.
Cohort 1  
Nov 2010 to 
May 2013
Cohort 2  
Apr 2011 to 
Nov 2013
Cohort 3  
Nov 2013 to 
May 2017






N in TBM case cohort 33 15 147 195
Outcome of hospitalization
   Unknown 26 (79%) 4 (27%) 23 (16%) 53 (27%)
   Known 7 (21%) 11 (73%) 124 (84%) 142 (73%)
      Discharged Alive 3 (43%) 4 (36%) 73 (59%) 80 (56%) 0.27
      Died 4 (57%) 7 (64%) 51 (41%) 62 (44%)
Odds Ratio (Mortality) and 95% CI (on imputed data)
   Assuming 50% of unknowns died
      Adjusted for ART status 1.5 (0.6,3.6) 2.0 (0.7,6.2) 1
       Adjusted for ART status and 
confirmed TBM
1.7 (0.7,4.4) 1.8 (0.6,5.6) 1
   Assuming 75% of unknowns died
      Adjusted for ART status 3.3 (1.3,8.4) 2.5 (0.8,7.8) 1





Overall median (IQR) time in hospital was 7 (4, 10) days among those who were known to be discharged alive, 
and 3 (1, 9) days among those who were known to have died in hospital
*P-value from Fisher’s exact test comparing KNOWN discharged alive vs KNOWN died; Odds ratios are the odds 
of being discharged alive, assuming 50% and 75% of those with unknown outcome died
was high in the cohort overall (44%), similar to other research 
settings with high HIV prevalence7,19,22,23. The adjusted model on 
imputed data found odds of in-hospital mortality were almost 
two fold higher in the earliest cohort, tested by CSF smear 
microscopy only, than that of that of the most recent cohort in 
whom Xpert (and culture) are routinely performed. Severity 
of TBM at presentation was similar over the study period 
and TBM treatment recommendations have not changed for 
Uganda, though other confounding factors may exist.
Although we lack data regarding time to treatment initiation, 
in this research setting Xpert results were obtained within 
24 hours, leading to prompt treatment in the 51 subjects who 
were positive by Xpert MTB/Rif in real-time and presumably 
contributing to reduced mortality. The proportion of ART expe-
rienced subjects increased significantly over time with the 
roll out of ART treatment in Uganda and because the parent 
trial in cohort one enrolled only ART naïve subjects24. Although 
ART status was not associated with mortality, we did adjust 
for ART in multivariable models due to the large discrepancy 
in ART status between cohorts.
Despite a non-significant decline in mortality, a current case- 
fatality rate of 41% remains unacceptably high and highlights 
the remaining work required to achieve the WHO goal of reducing 
TB-related deaths by 90% by 203025. Initiating treatment in 
the early stage of disease is the single most important factor 
in improving outcomes7. Earlier presentation to the hospital is 
essential for prompt diagnosis and treatment initiation, yet, 83% 
of our cohort presented with MRC grade II or III disease.
Once the patient presents to care, an affordable, rapid, and reli-
able test that can effectively confirm or rule out TBM is crucial 
for prompt diagnosis. In this predominantly HIV-positive TBM 
cohort, sensitivity of Xpert was 63% against the composite 
reference standard. Thus, even though results were available 
rapidly, Xpert missed over one in three cases. The next gen-
eration assay Xpert MTB/Rif Ultra has an analytic limit of 
detection of 15 colony forming units (CFU)/ml, compared to 
113 CFU/ml for Xpert26. Ultra appears to be significantly more 
sensitive than Xpert or culture for the diagnosis of TBM (95% 
versus 45% and 45% respectively, P<0.001)27. Whether Ultra 
can reduce diagnostic delay and improve outcome from TBM 
requires further prospective evaluation.
Where both Xpert and MGIT had been done, less than a third 
(23%, 17/74) of confirmed cases were positive by both modali-
ties. This is consistent with prior findings and is likely due to 
the relatively higher sensitivity of culture versus Xpert, and 
the ability of Xpert to detect dead TB bacilli13,27. Neither test 
performed better than the other (P=0.42).
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Figure 3. Illustration of odds of dying in cohort one and two compared to cohort three in a multivariate model. Odds ratios (and 95% 
confidence intervals) for death by the end of hospitalization comparing cohorts 1 and 2 to cohort 3, computed from multivariable logistic 
regression models with imputed data, adjusted for (1) ART status, and (2) ART status and definite TBM diagnosis. Data for patients with 
unknown outcome was imputed to assume that 50% within each cohort died, or that 75% died.
Until a highly sensitive assay is widely available, there is 
likely to be on-going heterogeneity in clinical practice regard-
ing initiation of empiric therapy for TBM. In our study, Mulago 
Hospital participants were treated for TBM on an empiric basis 
in under one quarter of cases as opposed to over three quarters 
of cases at Mbarara Hospital. Though empiric TBM therapy 
is potentially life-saving, significant risks such as side effects, 
drug-interactions and adjunctive steroids in an already immu-
nosuppressed population need to be considered. Ideally, a 
rapid, accurate test allows therapy for TB meningitis to be 
started promptly only in those who actually have TBM. Overall, 
the proportion with microbiologically confirmed TBM increased 
significantly from 3% in cohort one to 41% in cohort three 
(P<0.01). In cohort two, Xpert was only performed in cases 
where there was extremely high index of suspicion and empiric 
treatment was given only twice in those with a negative Xpert 
(4%, 2/56). The low number of empiric diagnoses during this 
period were likely due to over-confidence in Xpert’s ability to 
rule-out TBM. As understanding regarding the limitations of 
Xpert for the diagnosis of TBM became known, empiric TBM 
treatment rose14.
Limitations of this study include missing data on hospital 
outcomes and time to starting TB treatment, unbalanced 
numbers in each cohort including smaller numbers in earlier 
cohorts and lack of long-term outcome data. When imputing 
data in the model we assumed that either 50% or 75% of patients 
with unknown outcome actually died, which is a clinically 
reasonable judgment for this population4.
Here we present important data on rates of diagnos-
tic confirmation and TBM mortality during a period of TB 
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diagnostic evolution. There has been a significant increase in 
microbiological confirmation and a modest, albeit non-significant, 
decline in mortality since introduction of Xpert and culture in 
our study setting. An on-going multifaceted approach is needed 
to further reduce death and disability from TBM.
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Sean Wasserman  
University of Cape Town, Cape Town, South Africa 
Angharad Davis   
National Hospital for Neurology and Neurosurgery, University College London Hospitals, London, 
UK 
Many thanks for requesting us to review this article which addresses an important unanswered 
question in TB diagnostics. We have made specific points regarding each section of the 
manuscript as well as giving an overall impression.  
  
This prospective cohort studies observes differences in diagnosis and hospital outcomes related to 
TBM across three cohorts of patients recruited over a 6.5 year period in Uganda. The study aims to 
measure the impact on diagnosis and hospital outcomes with the addition of Gene Xpert testing 




The study design is unclear: is this a retrospective or post-hoc analysis of data collected 
from other studies? The nature of the parent studies should be mentioned.
○
The denominator is not clearly reported: the inclusion criteria for the current analysis 
appears to be “all meningitis suspects with a negative CSF cryptococcal antigen.” Were 558 
patients with negative CSF cryptococcal antigen test included in the analysis?
○
The conclusion that “in-hospital mortality has declined” seems exaggerated because this 
trend towards lower mortality over the study periods was not significant, and may have 




The inclusion criteria should be clearly defined and justified.○
Differences between the cohorts could have introduced bias towards improved outcomes 
(type 1 error): cohorts 1 and 2 at physician discretion, cohort 3 were systematically 
investigated. This should be addressed in the discussion.
○
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Please explain how the performance of a test (eg Xpert) can be compared to a reference 
standard that includes the test itself (“any positive CSF test - AFB smear, Xpert or culture”)?
○
Were the variables in the multivariate model selected a priori?○
Was ethics permission obtained for this sub-study/analysis?○
  
Results
The denominator is not clearly reported: the inclusion criteria for the current analysis 
appears to be “all meningitis suspects with a negative CSF cryptococcal antigen.” Were 558 
patients with negative CSF cryptococcal antigen test included in the analysis, or was it 195 
subjects that were treated for TBM? This should match the inclusion criteria, which appear 
to be any patient with suspected meningitis and negative CrAg testing.
○
A large proportion of patients in cohorts 2 and 3 were on ART at the time of presentation: 
this could alter their prognosis and bias the results. Although the model adjusted for this, it 
should be emphasised more in the discussion.
○
There is a discrepancy in the number of microbiologically proven cases: 
“Among the 76cases of microbiologically proven TBM”○
“Microbiological confirmation of TBM was made in 38% (74/195) of cases”○
○
Why was the number of confirmed cases so high in Cohort 2?○
The paragraph describing empiric treatment practices requires clarification: how was 
‘empiric treatment’ defined? The numbers appear to suggest that no patients with a 
confirmed diagnosis were empirically treated (ie empiric treatment = no microbiological 
confirmation). Suggest changing the terminology to make this clearer – 1. Treated based on 
positive result; 2. Treated without a positive result. It seems that in Mulago Hospital a 
higher proportion of treated patients had positive results, and therefore did not require 
‘empiric treatment.’ So, the important question seems to be why there was such a bug 
discrepancy in the number of confirmed cases between the two sites, allowing ‘empiric 
treatment’ to be avoided?
○
The denominator is again unclear for the diagnostic accuracy section: where do the “455 
tested” come from if only 195 cases were included in the study (or is it 558?). Suggest 
including a consort diagram to explain the patient populations for this study.
○
Suggest including a 2 x 2 table to demonstrate the performance of diagnostic tests. 
Although the sensitivity of Xpert is 63% compared to a reference standard, this this 




See comments related to discussion above○
The main (and probably only data-driven) conclusion is that more confirmed TBM cases 
were detected with the use of Xpert and culture. The authors did not convincingly show an 
improvement in outcomes. Any observed trends could be secular, or related to other 




The study observes three cohorts recruited from two parent trials. Although the data provides an 
important insight into the unanswered questions above, the suitability of the cohorts as 
comparators to one another does pose some limitation to how the results can be interpreted. 
Namely there is large variation between the observed cohorts in a number of aspects namely the 
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size of cohorts, ART status, and availability of follow up data. Although ART status had been 
accounted for in analysis, the impact of absent follow up data which is much more prominent for 
cohort 1 (79%) compared to cohort 3 (16%) should be made clearer in the discussion. Also, how 
were the patients allocated to cohort 1 and 2 during the overlapping study period (1stApril 2011 
until 28thMay 2013)? Were those where there was more diagnostic doubt allocated to receive 
testing with GeneXpert (and therefore subsequently included in cohort 2 than cohort 1?).. could 
this have affected outcomes observed between the two groups? 
  
It is possible that apart from the mentioned variables, that over time, other aspects may have 
influenced hospital outcome in these patients over a period where there has naturally been some 
advances made in TBM care besides the diagnostics discussed. For example the use of imaging 
diagnostics, time to treatment, availability of drugs, better understanding of supportive measures 
in TBM. I feel that these should form part of the discussion here and although they may not be 
quantifiable in this setting, should be acknowledged as possible factors for the observed 
differences over time. In this setting specifically were there changes in resource allocation? Did 
hospital facilities change?
 
Is the work clearly and accurately presented and does it cite the current literature?
Yes
Is the study design appropriate and is the work technically sound?
Partly
Are sufficient details of methods and analysis provided to allow replication by others?
Partly
If applicable, is the statistical analysis and its interpretation appropriate?
Yes
Are all the source data underlying the results available to ensure full reproducibility?
No source data required
Are the conclusions drawn adequately supported by the results?
Partly
Competing Interests: No competing interests were disclosed.
We confirm that we have read this submission and believe that we have an appropriate level 
of expertise to confirm that it is of an acceptable scientific standard, however we have 
significant reservations, as outlined above.
Author Response 26 Jun 2018
Fiona Cresswell, London School of Hygiene and Tropical Medicine, London, UK 
Thank you Dr Wasserman and Dr Davis for your many comments, questions and 
suggestions, which we will address this individually:  
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Abstract 
1. The study design is unclear: is this a retrospective or post-hoc analysis of data 
collected from other studies? The nature of the parent studies should be mentioned. 
 
The nature of the parent studies has been expanded in the methods section of the revised 
manuscript. We have also added further information to the abstract and clarified that this is 
a post-hoc analysis of prospective cohorts.  
 
2. The denominator is not clearly reported: the inclusion criteria for the current 
analysis appears to be “all meningitis suspects with a negative CSF cryptococcal 
antigen.” Were 558 patients with negative CSF cryptococcal antigen test included in 
the analysis? 
 
The main analysis for microbiological confirmation and mortality relates to the 195 people 
within the three TBM prospective cohorts. Of the 1672 screened any patient who received 
any testing for TBM (CSF AFB smear, Xpert or mycobacterial culture) during this period was 
eligible to be included in table 2 and the diagnostic accuracy of Xpert and culture analysis. 
Any patient who was ultimately treated for TBM (n=195) was eligible to be included in the 
three prospective TBM cohorts, and it was this group on whom the rate of microbiological 
confirmation and outcomes were compared. We have added a schematic diagram to the 
manuscript which i hope clarifies the nature of the study population.   
 
3. The conclusion that “in-hospital mortality has declined” seems exaggerated because 
this trend towards lower mortality over the study periods was not significant, and 
may have been due to other factors unrelated to changing diagnostics 
 
You are absolutely correct. We have changed to text in the abstract to read "Since 2010, as 
TBM diagnostics have evolved, microbiologically-confirmed TBM diagnoses have increased 
and there has been a non-significant decline in TBM in-hospital mortality. Due to multiple 




1. The inclusion criteria should be clearly defined and justified 
 
The following text has been added to the revised manuscript: 
"Adults presenting with suspected meningitis (headache and neck stiffness +/- vomiting, 
fever, seizures, focal neurological deficits, or altered consciousness), to Mulago National 
Referral Hospital, Kampala, and Mbarara Regional Referral Hospital, were assessed"   
"Participants with non-cryptococcal meningitis were not enrolled into the clinical trials but 
followed until hospital discharge".  
"Any patient who was ultimately treated for TBM was eligible to be included in one of the 
three TBM cohorts, on which rates of microbiological confirmation and outcomes were 
compared. Cohort was determined by what type of TB testing they had undergone".  
 
2. Differences between the cohorts could have introduced bias 
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This is a valid observation. Text stating "selection bias could have impacted on results" has 
been added to the discussion.  
 
3. Please explain how the performance of a test (eg Xpert) can be compared to a 
reference standard that includes the test itself (“any positive CSF test - AFB smear, 
Xpert or culture”)? 
 
Whilst we acknowledge this is an imperfect reference standard there is not a suitable 
reference standard that can be used in TBM diagnostic accuracy studies. Importantly, each 
of the tests is know to have a high specificity so the chance of false positives is extremely 
low, especially in a symptomatic population with a high disease prevalence. Latent class 
analysis would be a potential statistical approach that could be used in such cases which 
lack a perfect reference standard, and we would be interested to do such an analysis in 
future.  
 




5. Was ethics permission obtained for this sub-study/analysis? 
 
Yes, the informed screening consent process sought approval for both storage of 




1. The denominator is not clearly reported: the inclusion criteria for the current 
analysis appears to be “all meningitis suspects with a negative CSF cryptococcal 
antigen.” Were 558 patients with negative CSF cryptococcal antigen test included in 
the analysis, or was it 195 subjects that were treated for TBM? This should match the 
inclusion criteria, which appear to be any patient with suspected meningitis and 
negative CrAg testing. 
 
I hope the response to comment on abstract has clarified this.  
 
2. A large proportion of patients in cohorts 2 and 3 were on ART at the time of 
presentation: this could alter their prognosis and bias the results. Although the model 
adjusted for this, it should be emphasised more in the discussion. 
 
This has been emphasised in the discussion of the revised manuscript.  
 
3. There is a discrepancy in the number of microbiologically proven cases 
 
Thanks for spotting this typo. This has been corrected to 74.  
 
4. Why was the number of confirmed cases so high in Cohort 2 
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The review by Dr Hamers also made this comment. Please see response to his comment for 
a potential explanation.  
 
5. The paragraph describing empiric treatment practices requires clarification: how 
was ‘empiric treatment’ defined? The numbers appear to suggest that no patients 
with a confirmed diagnosis were empirically treated (ie empiric treatment = no 
microbiological confirmation). Suggest changing the terminology to make this 
clearer.  
 
Thank you. We have defined this more clearly in the methods.  
 
6. So, the important question seems to be why there was such a big discrepancy in the 
number of confirmed cases between the two sites, allowing ‘empiric treatment’ to be 
avoided? 
 
Both hospitals have the same available diagnostics so i believe the difference in empiric 
treatment relates to local or personal thresholds applied to the initiation of TB treatment in 
the absence of a confirmatory test. You will no doubt have observed different treatment 
thresholds amongst colleagues, especially faced with a critically ill patient. As Mbarara 
Hospital is a relatively small hospital with good longterm retention of staff, especially in the 
clinical research setting, it is possible that a handful of clinicians may have seen the majority 
of TBM cases and been more willing to initiate TB treatment despite negative tests than in 
Kampala where there is a bigger team and clinicians rotate regularly.    
 
7. Suggest including a consort diagram to explain the patient populations for this 
study.  
 
Thanks for this suggestion. We have included a schematic of patient flow from the 
screening population into the cohort. It is not a classic consort diagram since this 
population were not part of an RCT.  
 
8. Suggest including a 2 x 2 table to demonstrate the performance of diagnostic tests. 
 
We have added a 2x2 table.  
 
Discussion 
1. The main (and probably only data-driven) conclusion is that more confirmed TBM 
cases were detected with the use of Xpert and culture. The authors did not 
convincingly show an improvement in outcomes. Any observed trends could be 
secular, or related to other confounding factors resulting from different populations, 
selection criteria, management practices, etc.  
 
Indeed. We acknowledge the limitations of the data available to us and have tempered the 
conclusion accordingly in the revised manuscript.  
 
2. For example the use of imaging diagnostics, time to treatment, availability of drugs, 
better understanding of supportive measures in TBM. I feel that these should form 
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part of the discussion here and although they may not be quantifiable in this setting, 
should be acknowledged as possible factors for the observed differences over time. In 
this setting specifically were there changes in resource allocation? Did hospital 
facilities change? 
 
This a good thoughts and we concede that many potential confounders exist. However, we 
could show from our limited data that severity at presentation across cohorts was the same. 
Whilst the health services in the private sector have evolved in this time period the 
government facilities remain under resourced without access to routine blood tests and 
imaging. Thankfully access to TB medication has been stable for many years. Healthcare 
worker practices may certainly have changed and we recognise this as a potential 
confounder.  
 
Thank you again for your detailed review. I hope the responses and amendments are 
satisfactory.  
Competing Interests: nil
Reviewer Report 11 June 2018
https://doi.org/10.21956/wellcomeopenres.15907.r33231
© 2018 Hamers R. This is an open access peer review report distributed under the terms of the Creative 
Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited.
Raph L. Hamers   
Eijkman-Oxford Clinical Research Unit, Jakarta, Indonesia 
This is a large prospective study that assesses TBM diagnostics and mortality in 2 reference 
hospitals in Uganda, including 3 HIV adult cohorts that can be distuinguished by the routine use of 
different diagnostic testing approaches on CSF: 1) AFB only (2010-2013); 2) AFB+Xpert 
(uncentriguged CSF) (2011-2013); 3) AFB+Xpert (centriguged, large volume)+MGIT (2013-2017). The 
study is a commendable effort to improve care and outcomes of TBM in LMIC. It is well-written 
and presents unique and rich data that are very informative to clinicians who seek to improve 
outcomes of TBM. The authors report substantial achievements in improving access to and 




1. The title suggests that the aim of the study was to investigate if better TBM diagnostics can lead 
to improved survival. After reading the article, this question cannot be answered. The authors 
rightfully formulate their conclusion more prudently: “As TBM diagnostics have improved, 
microbiologically-confirmed TBM diagnoses have increased and in-hospital mortality has 
declined”. Indeed, many other factors could have influenced the differential outcomes across the 3 
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historical cohorts that span the time period of 2011-2017, and I feel the authors could present 
these complex factors in a more structured and comprehensive manner in the Discussion: 
- For instance, the main driver of the difference observed is the huge discrepancy between ART 
status across cohorts (0-61% on-ART) -is it at all possible to adjust for this major difference with 
statistical methods alone?  
- The authors note no major changes in treatment practices over time, although they also 
report substantial differences between the 2 hospitals in ability to confirm diagnosis and 
start empirical treatment, which may have impacted on outcomes (if varied with time). 
- Referral practices and general awareness among care providers may have improved in the study 
setting (the authors note they do not have data on time to Rx initiation), especially given that the 
authors have implemented 2 large clinical trials in the same period. 
- The patient case mix may have changed over time in many other ways (e.g. better nutrition, 
better education, lower TB incidence, better HIV diagnosis and treatment, etc) 
  
My recommendation is to reword the title, to avoid misleading the readership. 
  
2. The authors have (deliberately) done separate analyses on the 3 cohorts, and combining 
historical cohorts may have its limitations. Nonetheless, the combined cohort offers opportunities 
to attempt answering the main question. In this respect, it would be interesting if the authors 
could undertake a multivariate analysis of the combined cohort data to identify what are the main 
determinants of mortality (adjusting for time period). This could help to establish whether indeed 
the diagnostics influenced outcomes, or that the survival gain was mainly driven by other factors 




1. The % of microbiological confirmation is 3% in cohort #1, 87% in cohort #2, and 41% in cohort 
#3. It would be relevant to learn why the latest % seems to be lower than the middle one (despite 
better diagnostic protocols). 
  
2. The degree of agreement between Xpert and MGIT is very low (kappa 0.23). I would like to see a 
better explanation for this discrepancy, and how this knowledge can to be applied in 
recommendations for testing algorithms in practice.
 
Is the work clearly and accurately presented and does it cite the current literature?
Yes
Is the study design appropriate and is the work technically sound?
Partly
Are sufficient details of methods and analysis provided to allow replication by others?
Yes
If applicable, is the statistical analysis and its interpretation appropriate?
Yes
Are all the source data underlying the results available to ensure full reproducibility?
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Yes
Are the conclusions drawn adequately supported by the results?
Yes
Competing Interests: No competing interests were disclosed.
I confirm that I have read this submission and believe that I have an appropriate level of 
expertise to confirm that it is of an acceptable scientific standard, however I have 
significant reservations, as outlined above.
Author Response 26 Jun 2018
Fiona Cresswell, London School of Hygiene and Tropical Medicine, London, UK 
We thank Dr Hamers for his insightful and helpful comments.  
 
1. The title suggests that the aim of the study was to investigate if better 
TBM diagnostics can lead to improved survival. After reading the article, this question 
cannot be answered. 
 
In light of your observation we have changed the title to "Tuberculous meningitis diagnosis 
and outcomes during the Xpert MTB/Rif era: a 6.5-year retrospective cohort study in 
Uganda". We hope this better reflects what can actually be concluded from this 
retrospective data analysis.  
 
2. Indeed, many other factors could have influenced the differential outcomes across 
the 3 historical cohorts that span the time period of 2011-2017, and I feel the authors 
could present these complex factors in a more structured and comprehensive manner 
in the Discussion.  
 
Thank you for this suggestion. We have taken on board and revised the discussion to 
acknowledge the multiple potential unadjusted confounding factors and the inability to 
draw a conclusion about the impact of diagnostics on outcomes from the data we have 
available.  
 
3. The authors have (deliberately) done separate analyses on the 3 cohorts, and 
combining historical cohorts may have its limitations. Nonetheless, the combined 
cohort offers opportunities to attempt answering the main question. In this respect, it 
would be interesting if the authors could undertake a multivariate analysis of the 
combined cohort data to identify what are the main determinants of mortality 
(adjusting for time period). This could help to establish whether indeed the 
diagnostics influenced outcomes, or that the survival gain was mainly driven by other 
factors (e.g. ART). In my view, adding this analysis could strengthen the paper. 
 
Thank you for this suggestion. Assessing risk factors for mortality was not the primary 
intent of the paper but we agree this would make an interesting analysis in future. The TBM 
testing cohorts in this study generally represent testing time period and cohort is the 
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primary variable of interest for this study. Since ART use changed over time and definite 
TBM is associated with increased risk of mortality, these covariates were chosen to be 
included in adjusted analyses. Mortality was unknown for 27% of participants, so we 
conducted a series of models with imputations assuming that 50% within each cohort died, 
or that 75% died (both within the expected mortality range for this population).  Six 
multivariable models of in-hospital mortality were run and all cohorts were included in all 
models. Cohort 3 was chosen as the reference category for presenting the odds ratios of 
interest since it represents the most current testing era. In all models, neither ART nor 
definite TBM status had a significant association with in-hospital mortality. All models run 
include all cohorts and the odds ratios comparing cohorts from the adjusted models are 
presented in Figure 4 in the (revised) manuscript. 
 
4. The % of microbiological confirmation is 3% in cohort #1, 87% in cohort #2, and 41% 
in cohort #3. It would be relevant to learn why the latest % seems to be lower than the 
middle one (despite better diagnostic protocols).  
 
This is an interesting observation and we believe relates to two factors: 
a) In cohort 2, during the initial period after Xpert introduction, it was only being used on 
cases with an extremely high clinical index of suspicion so there was a selection bias in 
population tested.  
b) The % of confirmed case amongst the total number treated for TBM in cohort 2 appears 
spuriously high as the amount of empiric treatment was very low during the cohort. One 
potential reason is that there was an over confidence in Xpert's ability to be able to rule out 
TBM. In subsequent years a number of papers showed that the negative predictive value of 
Xpert is such that a negative test result should not deter TB treatment and empiric 
treatment was used more frequently again in out setting.  
 
5. The degree of agreement between Xpert and MGIT is very low (kappa 0.23). I would 
like to see a better explanation for this discrepancy, and how this knowledge can to be 
applied in recommendations for testing algorithms in practice. 
 
This is another interesting observation, and a somewhat surprising finding to us also. We 
have not elaborated in the discussion in the interest of brevity but possible explanations are 
mentioned here: 
Positive on Xpert whilst negative on culture: 
We lack data about the number of cases in the cohort who were on TB treatment at the time 
of lumbar puncture. It is plausible that if TB treatment had been initiated in the days or 
weeks prior to the CSF analysis the mycobacterium may have been rendered non-viable for 
culture. In our setting many patients present with a disseminated TB picture, some of whom 
have been coughing for several weeks prior to development of neurological symptoms and 
already initiated on antituberculous therapy from outpatient settings. We hope to capture 
this data more comprehensively in prospective studies.   
Positive on culture whilst negative on Xpert: 
Culture has a lower limit of detection that Xpert so patients with bacillary burdens on the 
<100CFU/ml region would likely be identified by culture only.  
Considerations for future testing algorithms: 
It is hopeful that the next generation assay Xpert MTB/Rif 'Ultra' will have a limit of 
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detection similar to that of culture, so given that it can also detect non-viable bacilli, it is 
likely to perform better the culture in the diagnosis of TBM (as was the case in Bahr N. 
Lancet ID. 2018).  
Testing algorithms must be customised and take into consideration the setting, HIV-
prevalence, cost and the volume of CSF available for testing, amongst other things. Splitting 
a small CSF sample between multiple assays is likely to be counterproductive. In our setting 
we would recommend Ultra as the initial CSF test for TBM (in patients with a negative CSF 
cryptococcal antigen lateral flow assay). Culture remains an important adjunctive test 
especially in patients where there is a risk of drug resistance.  
 
We have submitted a revised manuscript and hope these changes and responses are to Dr 
Hamer's satisfaction.  
Competing Interests: nil
Reviewer Report 06 June 2018
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Tom Boyles   
Wits Reproductive Health and HIV Institute, University of the Witwatersrand, Johannesburg, South 
Africa 
Thank you for the opportunity to review this article which describes the investigation, treatment 
and outcomes of a cohort of mostly HIV infected adults in Uganda who were suspected of having 
TB meningitis. It is well written and easily reproducible by others. 
 
The title asks the question of whether improved diagnostics can reduce mortality in TBM. It might 
be better to say ‘Have improved diagnostics improved outcomes?’ My view of the data is that it 
provides very limited evidence that improved diagnostics have improved outcomes of TBM in this 
cohort. The small improvements in outcome over time are statistically non-significant and due to 
the observational design are likely to be influenced by numerous unmeasured confounding 
factors. For example, the experience of clinician may well have changed over time, we know that 
empiric treatment was used differently in the 2 centres but it might also have changed over time. 
Part of the work-up of a patient with suspected TBM is a search for extra-neural TB and we do not 
know how this changed over time although it is likely that Xpert MTB/RIF was used for non-CSF 
samples in later cohorts compared to earlier, the same might be said for urine LAM. 
 
My view as a reader is therefore that this data does not provide convincing evidence that the 
change in diagnostics was the driver of the small changes in mortality. It must be remembered 
that new diagnostics also have the potential to worsen outcomes, particularly if clinicians miss-
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interpret negative tests as ruling out the condition as might well occur with Xpert MTB/RIF and 
TBM. 
 
I think that this well written work definitely deserves to be published but feel that the conclusions 




The abstract says that all 1672 patients were HIV infected but in the results section is says 96% 
were HIV infected so there is a discrepancy. 
 
Last line, para 1 of introduction, probably remove word ‘to’. 
 
Last line. Para 3 of introduction- It is not that Xpert cannot substitute for clinical judgement- Xpert 
is used to enhance clinical judgement, it’s just that the  poor sensitivity means that when negative 
it has limited influence on decision making 
 
Statistical methods- the uniform case definition is probable or definite TBM- do the authors think 
this is a reasonable reference standard for other tests? My view is that the threshold for treating 
TBM is very low and that patients with possible/probably or definite TBM should receive treatment 
and therefore this would be a more appropriate reference standard- what are your views on that? 
 
Methods- Not clear if there were 76 or 74 microbiologically proven cases 
 
Discussion- Para 1, repeat of ‘that of’ 
 
Discussion- Para 4, First sentence implies that tests are the only answer to the diagnosis of TBM, 
what about clinical prediction rules relying on clinical data- although so far they have not been 
very successful, neither have tests so a robust CPR may negate the need for tests. 
 
Discussion- Para5, Do the authors really think there are dead bacilli in CSF? Some of the authors 
have argued the opposite in their recent paper on Xpert Ultra so you can’t have it both ways. 
 
Is the work clearly and accurately presented and does it cite the current literature?
Yes
Is the study design appropriate and is the work technically sound?
Yes
Are sufficient details of methods and analysis provided to allow replication by others?
Yes
If applicable, is the statistical analysis and its interpretation appropriate?
Yes
Are all the source data underlying the results available to ensure full reproducibility?
Yes
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Are the conclusions drawn adequately supported by the results?
Partly
Competing Interests: No competing interests were disclosed.
Reviewer Expertise: Clinical management of patients with HIV and meningitis. The interpretation 
of tests and thresholds for treatment.
I confirm that I have read this submission and believe that I have an appropriate level of 
expertise to confirm that it is of an acceptable scientific standard, however I have 
significant reservations, as outlined above.
Author Response 26 Jun 2018
Fiona Cresswell, London School of Hygiene and Tropical Medicine, London, UK 
Dear Dr Boyles,  
 
Thank you for providing a considered and constructive of our paper. I'd like to respond to 
each comment in turn.  
 
1. The findings provide limited evidence that improved diagnostics have improved 
outcomes of TBM in this cohort and due to the observational design are likely to be 
influenced by numerous unmeasured confounding factors. I think that this well 
written work definitely deserves to be published but feel that the conclusions should 
reflect a greater level of uncertainty. 
 
We acknowledge the limitations of the retrospective data we present and the inability to 
account for a multitude of other confounding factors. The title of the manuscript has been 
changed to "Tuberculous meningitis diagnosis and outcomes during the Xpert MTB/Rif era: 
a 6.5-year retrospective cohort study in Uganda". In the conclusion of the revised 
manuscript we given more emphasis to uncontrolled confounding factors the fact that the 
data on impact of improved diagnostics on outcomes in inconclusive.  
 
2. Part of the work-up of a patient with suspected TBM is a search for extra-neural TB 
and we do not know how this changed over time although it is likely that Xpert 
MTB/RIF was used for non-CSF samples in later cohorts compared to earlier, the same 
might be said for urine LAM. 
 
Indeed, sputum samples may be undergone testing with Xpert to assist in the diagnosis of 
TBM in  cohort 3. TB-LAM has only become available in 2018 in Uganda so this will not have 
impacted our study which concluded in May 2017.  
 
3. It must be remembered that new diagnostics also have the potential to worsen 
outcomes, particularly if clinicians miss-interpret negative tests as ruling out the 
condition as might well occur with Xpert MTB/RIF and TBM. 
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I completely agree. The delay in waiting for a diagnostic test result must also be recognised, 
which can be several days in many hospital settings. Bring on an accurate bedside POCT.  
 
4. The abstract says that all 1672 patients were HIV infected but in the results section 
is says 96% were HIV infected so there is a discrepancy. 
 
Thanks for pointing out this oversight. I have added the word predominantly to the 
abstract.  
 
5. Last line, para 1 of introduction, probably remove word ‘to’. 
 
Well spotted. Thank you.  
 
6. Last line. Para 3 of introduction- It is not that Xpert cannot substitute for clinical 
judgement- Xpert is used to enhance clinical judgement, it’s just that the  poor 
sensitivity means that when negative it has limited influence on decision making.  
 
The text of the revised manuscript has been changes to read "a negative Xpert result has 
limited influence on clinical decision making".  
 
7. Statistical methods- the uniform case definition is probable or definite TBM- do the 
authors think this is a reasonable reference standard for other tests? My view is that 
the threshold for treating TBM is very low and that patients with possible/probably or 
definite TBM should receive treatment and therefore this would be a more 
appropriate reference standard- what are your views on that? 
 
This is a good discussion point. Where is the correct place to draw the line? The HIV co-
infection makes this particularly challenging as CMV meningoencephalitis, toxoplasmosis, 
PML etc can muddy the water further. In Uganda, in our HIV/TBM cases 1/3rd have CSF 
WBC<5 which can mean the points scored in the CSF category are fewer. Furthermore in 
resource constrained settings access to neuroimaging and extra neural sampling can be 
limited which again affects the ability to fully characterise the case. It would be completely 
acceptable to include 'possible' in the reference standard but we chose 'probable and 
definite' as we were concerned that the 'possibles' may include other HIV-realted 
neuropathologies.  
 
8. Methods- Not clear if there were 76 or 74 microbiologically proven cases 
 
Thanks for pointing out this typo. The test has been corrected to 74.  
 
9. Discussion- Para 1, repeat of ‘that of’ 
 
Well spotted again. Thank you.  
 
10. Discussion- Para 4, First sentence implies that tests are the only answer to the 
diagnosis of TBM, what about clinical prediction rules relying on clinical data- 
although so far they have not been very successful, neither have tests so a robust CPR 
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may negate the need for tests. 
 
I agree there is seldom a perfect test and clinical prediction rules can be extremely useful in 
areas where access to tests is limited. I look forward to seeing a CPR that can accurately 
distinguish TBM from other HIV-related brain infections / pathology and commend 
researchers in this pursuit.  
 
Discussion- Para5, Do the authors really think there are dead bacilli in CSF? Some of 
the authors have argued the opposite in their recent paper on Xpert Ultra so you can’t 
have it both ways. 
 
The presence of MTB DNA in the CSF of a immunocompromised adult with clinical 
meningitis in a TB endemic setting almost certainly represents TBM. However it may not 
always be possible to culture organisms as they may have been rendered non-viable by 
recent TB treatment, inflammatory response or delays in processing.  
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